GlassScriptPhysician profile
Nimesh Patel
NPI 1588643779
$5,261.60
in general payments reported to CMS, 2019-2025
29 companies · $1,272 in 2025
The $1,272 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $812 · 2020: $364 · 2021: $752 · 2022: $445 · 2023: $765 · 2024: $852 · 2025: $1,272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,573 · Education: $316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,573.09 |
| Education | $315.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $977.14 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $539.32 | 2019-2025 | Tavneos, Krystexxa, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $471.64 | 2019-2025 | Jardiance |
| Opko Pharmaceuticals, LLC | $453.94 | 2020-2025 | Rayaldee |
| Akebia Therapeutics INC | $434.89 | 2020-2025 | Vafseo |
| Vifor Pharma, INC. | $427.78 | 2019-2024 | Veltassa, Korsuva |
| Janssen Pharmaceuticals, INC | $277.19 | 2019-2020 | |
| Horizon Therapeutics Plc | $228.91 | 2021-2023 | Krystexxa |
| Otsuka America Pharmaceutical, INC. | $187.27 | 2021-2025 | Voyxact, Jynarque |
| Travere Therapeutics, INC. | $173.95 | 2023-2025 | Filspari |
| Ardelyx, INC. | $169.60 | 2023-2024 | Xphozah 30 Mg, Ibsrela |
| Abbott Laboratories | $135.27 | 2023 | Pressurewire |
| Medtronic Vascular, INC. | $124.99 | 2019 | |
| Calliditas Therapeutics US INC. | $96.16 | 2022-2025 | Tarpeyo |
| Providence Medical Technology, INC. | $92.85 | 2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $63.26 | 2022-2023 | Syfovre |
| Novartis Pharmaceuticals Corporation | $58.88 | 2024-2025 | |
| Lilly USA, LLC | $53.56 | 2024-2025 | Jardiance |
| Glaxosmithkline, LLC. | $39.81 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.19 | 2019-2021 | |
| Astellas Pharma US INC | $35.11 | 2025 | Izervay |
| Ultragenyx Pharmaceutical INC. | $34.71 | 2021 | |
| Mallinckrodt Enterprises LLC | $29.05 | 2019 | |
| Renalytix Ai, INC. | $23.68 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Fresenius USA Marketing, INC. | $22.94 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.90 | 2025 | |
| Mallinckrodt Hospital Products INC. | $18.61 | 2022 | |
| Scpharmaceuticals INC. | $15.75 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $15.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nimesh Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.